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1268myocardial infarction (MI), is a
priority for reducing the burden
of cardiovascular disease. Al-
though genomewide surveys of
genomic variation and gene ex-
pression can identify loci associ-
ated with CAD (1–3), few can
serve as biomarkers for cardio-
vascular events (4).
Aspirin is prescribed for the
prevention of cardiovascular events,
suggesting that aspirin interacts
with biological pathways that may
underlie these events. Platelet
function assays are a surrogate bio-
marker for the effects of aspirin and
are associated with cardiovascular
events (5). However, platelet func-
tion testing is not widely avai-
lable, primarily because of technical
complexity. By contrast, whole-
blood ribonucleic acid (RNA)
proﬁling using polymerase chain
reaction (PCR)–based assays is
currently a widely available di-
agnostic testing platform (6,7).
Therefore, we hypothesized thataspirin could be used as a probe in conjunctionwithwhole-blood
RNAproﬁling to elucidate novel biomarkers for platelet function
in response to aspirin and for cardiovascular outcomes.Methods
Platelet function outcomes in healthy volunteer cohorts
at Duke University Medical Center. We previously
described (8) the healthy volunteer discovery cohort (HV1) and
the healthy volunteer validation cohort (HV2) (Online Fig. 1)
and the platelet function score (PFS), a composite metric of
the following platelet function assays: PFA-100 (collagen/
epinephrine; Siemens Healthcare, Erlangen, Germany)
closure time and the areas under the optical aggregometry curve
induced by adenosine diphosphate (10, 5, and 1 mmol/l),
epinephrine (10, 1, and 0.5 mmol/l), and collagen (5 and
2 mg/ml). We measured the PFS and mean platelet volume
(MPV) in HV1 (n ¼ 50) after 2 weeks of dosing with
325 mg/day non–enteric-coated, immediate-release aspirin
and HV2 (n ¼ 53) after 4 weeks of dosing with 325 mg/day
aspirin. In both cohorts, whole-blood RNA was collected
into PAXgene Blood RNA tubes (Becton Dickinson and
Company, FranklinLakes,New Jersey) before and after aspirin
exposure and stored at 80C until microarray proﬁling.
Platelet count was measured in platelet-rich plasma in HV1.
Because 3 subjects in HV2 had participated in HV1, they
were dropped fromHV2, leaving 50 uniqueHV2 subjects. The
Duke UniversityMedical Center (DUMC) institutional review
board approved the study protocols.Platelet function outcomes in patients at risk for cardio-
vascular events at George Washington University. We
previously described (9) the outpatient cardiology cohort
(OPC) (Online Fig. 1), treated with 81 mg/day aspirin and
assessed using the VerifyNow Aspirin Test (Accumetrics,
Inc., San Diego, California) and whole-blood RNA
microarray analysis.
Clinical outcomes in DUMC patients. CATHETERIZATION
GENETICS BIOREPOSITORY. The Catheterization Genetics
(CATHGEN) biorepository has banked, whole-blood RNA
in PAXgene tubes from DUMC patients from the time of
cardiac catheterization, baseline medical history, and follow-
up for all-cause death and MI (10,11). Two cohorts had
available microarray data (Online Fig. 2): in the observational
cohort, 224 sequential samples were selected for RNA
analysis, of which 191 had sufﬁcient RNA for microarray
analysis, and the case-control cohort consisted of partici-
pants who had experienced death or MI (n ¼ 250) after their
index catheterization and age-matched, sex-matched, and
race-matched controls (n¼ 250) who were free of death orMI
for >2 years after cardiac catheterization (12). Four hundred
forty-seven had sufﬁcient RNA for microarray analysis; 44
overlapped with the observational cohort and were dropped,
leaving 403 subjects for analysis.
Follow-up for death and MI was ascertained in both
cohorts in October 2011; the median follow-up duration was
3.8 years. Patients with incomplete follow-up were censored
at the time of last contact. Patients who had histories of
cardiac transplantation at the time of catheterization (n ¼ 5),
died within 7 days (n ¼ 1), or failed quality control (n ¼ 1)
were excluded. The remaining datasets left 190 samples in
the observational cohort (48 death or MI events) and 397
(202 death or MI events) in the case-control cohort.
RNA extraction, labeling, microarray hybridization,
quality control, and normalization. See the Online
Appendix for full details. Two microarray platforms were
used: the Affymetrix U133A2 array (HV1, before aspirin;
Affymetrix, Santa Clara, California) and the U133 Plus 2.0
array (all others). The robust multichip average method was
used for normalization.
Real-time PCR. See the Online Appendix for full details.
Forty-ﬁve transcripts were selected for veriﬁcation in the
original RNA samples on the basis of 2 criteria: 1) the
strength of correlation of the probe set with PFS; and 2) the
strength of membership between the probe set and the set of
coexpressed genes of interest.
Platelet puriﬁcation, protein sample preparation, and
proteomics analysis by liquid chromatography–mass
spectrometry/mass spectrometry. See the Online
Appendix for full details.
Statistical analysis. The raw and normalized microarray
data are available in the Gene Expression Omnibus for the
OPC cohort (GSE38511). The data for the HV1, HV2,
and CATHGEN cohorts are available through the Database
of Genotypes and Phenotypes (phs000548.v1.p1 and
phs000551.v1.p1). Unless stated otherwise, all tests were 2
Figure 1 The Aggregate Expression of a Set of Coexpressed Whole-Blood Genes Correlates With Platelet Function in Response to Aspirin
Two independent cohorts of healthy volunteers were exposed to 325 mg/day aspirin, followed by whole-blood microarray proﬁling. Platelet function was assessed by the platelet
function score (PFS) (8). The aggregate expression of a set of coexpressed genes (aspirin response signature [ARS], x-axis) is plotted against the PFS (y-axis) after aspirin
exposure. Pearson’s correlation coefﬁcients and p values are reported.
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1269sided and were performed using R version 2.10.0 (R
Foundation for Statistical Computing, Vienna, Austria) or
MATLAB version R2010b (The MathWorks, Natick,
Massachusetts); p values <0.05 were considered signiﬁcant.
DISCOVERY OF COEXPRESSED GENE SETS ASSOCIATED WITH
PFS: FACTOR MODELING. The HV1, post-aspirin robust
multichip average normalized data were nonspeciﬁcally
ﬁltered (i.e., without regard to PFS) to remove probes withFigure 2
The ARS Is Associated With Platelet Function in
Patients at Risk for Cardiovascular Disease
Patients treated with 81 mg/day aspirin were assessed using the VerifyNow
Aspirin Test (9). Three categories of patients were proﬁled by microarray on the
basis of their aspirin response units (ARU): aspirin resistant (AR; ARU >550), high
normal (HN; 500 < ARU <550), and aspirin sensitive (AS; ARU <550). Aspirin
response signature (ARS) values for each group are plotted and compared using
2-sample Student t tests. p values are 1-sided.mean expression <2.0 (i.e., the gene was not expressed in
whole blood) or with variance <0.25 (i.e., the gene was
homogenously expressed), resulting in 2,929 probe sets for
subsequent analysis. To discover “factors,” or sets of coex-
pressed genes representative of biological pathways, we used
Bayesian factor regression modeling (13,14) in an unsuper-
vised fashion (i.e., without regard to PFS). Each of the probe
sets used to estimate a particular factor can be interpreted as
a measurement of the activity of some (potentially unknown)
biological pathway. Each sample can then be assigned a
“factor score,” which represents the aggregate expression of
the transcripts within a factor. The factor scores can then be
used for association with the phenotype of interest in
subsequent analyses.
FACTOR PROJECTION, GENE MEMBERSHIP WITHIN A FACTOR,
COMPARISON OF FACTOR GENE LISTS WITH SELECTED GENE
SETS, AND COEXPRESSION OF TRANSCRIPTS REPRESENTED BY
A FACTOR BEFORE AND AFTER ASPIRIN EXPOSURE. See the
Online Appendix for full details.
CORRELATIONS BETWEEN FACTOR SCORES AND PLATELET
FUNCTION. Pearson’s correlation analysis was used to test for
association between a factor and PFS inHV1 andHV2. In the
second validation cohort, OPC, we chose a 1-sided Student t
test because we hypothesized a lower factor score in the
aspirin-resistant versus aspirin-sensitive groups.
Linear regression was used to assess the independent
association of factor scores and PFS after accounting for log-
transformed MPV and/or platelet count.
CORRECTION FOR MULTIPLE HYPOTHESIS TESTING. Because
HV1 was a hypothesis-generating pilot study, we did not
adjust p values. In the ﬁrst validation cohort, HV2, we
adjusted p values using Bonferroni correction. In the second
validation cohort, we performed only 1 hypothesis test.
ANALYSES OF REAL-TIME PCR DATA. The expression of each
selected transcript relative to the 3 reference genes was
Figure 3 RT-PCR–Based Assays Verify the Microarray-Based Gene Expression Values for ARS Genes
Real-time polymerase chain reaction (RT-PCR) assays were designed to verify selected transcripts represented by the aspirin response signature (ARS) in the healthy volunteer
validation cohort. The deltaCq for each assay was correlated with the robust multichip average–normalized probe set expression for the corresponding ARS gene using Pearson’s
correlation (see Online Table 2). For the 4 genes with the highest PCR versus microarray-based correlations (ITGA2B, MYL9, TREML1, and MPL), we plot the relative quantity
(2deltaCq, x-axis, log-scale) versus the corresponding probe set expression (y-axis), correlation coefﬁcient, and p value.
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with the corresponding microarray probe set or PFS using
Pearson tests of correlation.
PLATELET PROTEOMIC DATASET ANALYSIS. See the Online
Appendix for full details.
ANALYSES OF CATHGEN COHORTS. Logistic or Cox propor-
tional hazards regression models were created in the case-
control or observational cohort, respectively, to test for
association between a factor and death or MI. Each model
tested the factor alone as well as after controlling for
baseline variables (Online Table 6) associated with the
factor of interest. The assumption of proportional hazards
for each Cox model was met. Odds ratios (ORs) (or hazard
ratios), 95% conﬁdence intervals (CIs), and p values are
reported.
To assess the independent association between a factor and
death or MI, logistic regression models were built on the
combined CATHGEN cohorts by forcing Framingham risk
factors (age, sex, smoking, diabetes, hypertension, and hyper-
lipidemia), African-American race, cohort, platelet count, andthe presence of CAD (deﬁned as a CAD index [15] >32
or a history of coronary artery bypass surgery, MI, or percuta-
neous coronary intervention) into the model and adding
the factor score or individual probe set gene expression.
To assess the incremental prognostic value of gene expression,
we compared the performance of competing models (risk
factors with or without factor or probe set expression), using
the areas under the receiver-operating characteristic curve
(16), the net reclassiﬁcation index (using risk categories
of <10%, 10% to 20%, and >20%) (17) or category-free net
reclassiﬁcation index (18), and the integrated discrimination
improvement (17).
Results
Discovery and validation of a set of coexpressed genes in
whole blood that correlate with platelet function on
aspirin. In the discovery cohort (HV1), we identiﬁed 20
factors (numbered 1 to 20) (Online Table 1) representing
sets of highly correlated, coexpressed genes. To test the
hypothesis that 1 or more of these gene sets were associated
with PFS on aspirin, we correlated each set with PFS inHV1
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1271and identiﬁed “factor 14” (Fig. 1, Discovery Cohort) and
“factor 3” (r ¼ 0.27, p ¼ 0.05). In the ﬁrst validation cohort
(HV2), we found a signiﬁcant association between factor 14
and PFS, with the same strength and direction as observed in
HV1 (Bonferroni-adjusted p ¼ 0.03; Fig. 1, Validation
Cohort #1), thus validating this association, but factor 3 was
not associated with PFS inHV2.We further validated factor
14 with VerifyNow test results in the OPC cohort (Fig. 2).
Thus, factor 14, which we named the “aspirin response
signature” (ARS), was validated in 2 independent cohorts as
a set of coexpressed genes associated with platelet function
on aspirin.
To verify the microarray-based expression of the ARS
transcripts, we selected 45 of the 60 genes (see Methods for
selection criteria) for veriﬁcation in whole-blood RNA from
the HV2 cohort. Using real-time polymerase chain reaction
(RT-PCR), 42 of 45 transcripts were signiﬁcantly correlated
with their microarray-based expression, with 16 of these 42
transcripts, including ITGA2B, TREML1, MYL9, and
MPL, strongly (r > 0.80) correlating with microarray-based
gene expression (Fig. 3, Online Table 2). For the majority of
transcripts, there was concordance between both the RT-
PCR and microarray correlations with PFS (Online
Table 3, Online Fig. 1). Therefore, RT-PCR assays vali-
date the microarray-based expression associations with PFS
for most ARS transcripts.
ARS transcripts are primarily of platelet origin. We
observed that the transcripts with the strongest correla-
tions with PFS (Table 1) mapped to several well-known
platelet transcripts: ITGA2B, CLU, IGF2BP3, GP1BB,
and SPARC. On the basis of this observation, we
hypothesized that transcripts represented by the ARS
were of platelet origin. To test this hypothesis, we
examined the overlap and enrichment of the 60 genes
represented by the ARS with pre-deﬁned gene sets
speciﬁc to various peripheral blood cell types. Up to 24 of
the 60 ARS genes signiﬁcantly overlapped with platelet-
speciﬁc or megakaryocyte-speciﬁc genes, whereas none
overlapped with nonplatelet peripheral blood cell–type
genes (Online Tables 4 and 5). Furthermore, in the
CATHGEN cohorts, we found the strongest correlation
between expression of the ARS and platelet count (r ¼
0.41, p < 2  1016), with no strong positive correlations
with any other peripheral blood cell type counts: white
blood cells (r¼0.01, p¼ 0.87), lymphocytes (r¼0.25,
p ¼ 1.2  105), neutrophils (r ¼ 0.16, p ¼ 0.01), or
monocytes (r ¼ 0.06, p ¼ 0.27).
To conﬁrm the platelet origin of the ARS genes, we
analyzed puriﬁed platelet lysates by label-free proteomics in
the HV2 cohort. We identiﬁed 17 proteins from the ARS
gene set in the proteomics dataset, of which 6 were associ-
ated with PFS, including ITGA2B, ITGB3, and MYL9
(Table 2), all in the same direction as their corresponding
transcripts. Therefore, from these data, we conclude that
a large number of ARS transcripts originate in platelets and
are thus reporting on a coexpressed pathway of platelettranscripts and proteins associated with platelet function on
aspirin.
Because MPV is associated with platelet function (19) and
the platelet origin of ARS transcripts, we assessed the extent
to which the association between ARS and PFS was
confounded by platelet volume or count. After controlling for
MPV, the ARS remained signiﬁcantly (adjusted regression
coefﬁcient for ARS ¼ 0.5, standard error ¼ 0.2, p ¼ 0.05
for HV1; adjusted regression coefﬁcient for ARS ¼ 0.87,
standard error ¼ 0.4, p ¼ 0.03 for HV2) associated with
PFS. Furthermore, in HV1, in which platelet count and
volume were both measured, the ARS remained signiﬁcantly
(0.5  0.2, p ¼ 0.04) associated with PFS after their
inclusion. Therefore, the association between ARS and
platelet function is independent of other readily available
platelet parameters, such as count and MPV.
Before the administration of aspirin, the ARS is not
associated with platelet function. Because pre-aspirin
platelet function is a strong predictor of post-aspirin platelet
function (8), we tested the hypothesis that the aggregate
expression of the ARS genes was correlated with native pre-
aspirin PFS. In neither HV1 nor HV2 did we observe
a correlation between the ARS and pre-aspirin PFS (Fig. 4).
Despite the absence of a correlation with PFS before aspirin,
the ARS genes were similarly coexpressed before and after
aspirin exposure (Online Fig. 2). Therefore, although the
ARS genes are highly correlated with one another before
aspirin exposure, their aggregate expression does not appear
to contribute to native pre-aspirin platelet function. Instead,
the expression of the ARS genes speciﬁcally reﬂects platelet
function on aspirin.
The ARS is an independent prognostic biomarker for
cardiovascular events. Because of the association of the
ARS with platelet function on aspirin and aspirin’s role in
preventing cardiovascular events, we tested the hypothesis
that the ARS was associated with the risk for death or MI in
2 independent patient cohorts. In both the case-control and
observational cohorts, the ARS was signiﬁcantly associated
with death or MI in univariate analyses (OR: 1.2; 95% CI:
1.04 to 1.4; p ¼ 0.04; and hazard ratio: 1.4; 95% CI: 1.1 to
1.7; p ¼ 0.002, respectively). The majority of the individual
transcripts represented by the ARS were also associated with
death or MI in both cohorts (Online Table 7).
To determine the extent to which the ARS or an indi-
vidual probe set for ITGA2B was an independent prognostic
biomarker for events, we combined the CATHGEN
cohorts and found that the ARS (OR: 1.3; 95% CI: 1.1 to
1.5; p ¼ 0.001) or the microarray-based expression of
ITGA2B (probe set 206494_s_at; OR: 1.5; 95% CI: 1.2 to
1.8; p ¼ 0.0001) were independently associated with death
or MI after adjustment for Framingham risk factors (20),
race, platelet count, and the presence of angiographic CAD.
To further assess the potential use of the ARS as a risk
biomarker, we tested the hypothesis that the ARS or ITGA2B
probe set expression would improve measures of discrimina-
tion. Compared with a model using clinical risk factors alone,
Table 1 Genes Represented by the ARS and Their Correlations With Platelet Function With Aspirin
Affymetrix Probe ID Gene Symbol
Gene
Description
Combined PFS
Beta Coefﬁcient*
Combined
p Value
Factor 14 NA NA 0.76088 0.0017
Individual factor 14 transcripts
208782_at FSTL1 Follistatin-like 1 1.6579 0.0003
201059_at CTTN Cortactin 1.2817 0.0015
201906_s_at CTDSPL CTD (RNA polymerase II,
polypeptide A) small phosphatase–like
1.3795 0.0025
1555659_a_at TREML1 Triggering receptor expressed on myeloid
cells–like 1
1.0767 0.0034
212667_at SPARC Secreted protein, acidic, cysteine-rich
(osteonectin)
1.214 0.0048
216956_s_at ITGA2B Integrin, alpha 2b (platelet glycoprotein IIb
of IIb/IIIa complex, antigen CD41)
1.0689 0.0048
230942_at CMTM5 CKLF-like MARVEL transmembrane domain
containing 5
1.1641 0.0061
57588_at SLC24A3 Solute carrier family 24 (sodium/potassium/calcium
exchanger), member 3
1.3053 0.0063
207550_at MPL Myeloproliferative leukemia virus oncogene 0.931 0.0066
219090_at SLC24A3 Solute carrier family 24 (sodium/potassium/calcium
exchanger), member 3
1.1123 0.0080
208791_at CLU Clusterin 0.9584 0.0085
206494_s_at ITGA2B Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa
complex, antigen CD41)
0.7279 0.0087
227189_at CPNE5 Copine V 1.2062 0.0088
220496_at CLEC1B C-type lectin domain family 1, member B 1.2077 0.0090
206493_at ITGA2B Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa
complex, antigen CD41)
0.8966 0.0094
206049_at SELP Selectin P (granule membrane protein 140kDa,
antigen CD62)
1.1642 0.0104
203819_s_at IGF2BP3 Insulin-like growth factor 2 mRNA binding protein 3 1.2947 0.0123
225354_s_at SH3BGRL2 SH3 domain binding glutamic acid-rich protein–like 2 1.0895 0.0146
207808_s_at PROS1 Protein S (alpha) 1.1049 0.0174
207206_s_at ALOX12 Arachidonate 12-lipoxygenase 0.8756 0.0207
212813_at JAM3 Junctional adhesion molecule 3 1.0454 0.0215
1560262_at LRRC32 Leucine-rich repeat-containing 32 0.9376 0.0226
204628_s_at ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa,
antigen CD61)
0.968 0.0242
214146_s_at PPBP Proplatelet basic protein (chemokine
[C-X-C motif] ligand 7)
0.713 0.0243
211026_s_at MGLL Monoglyceride lipase 1.0027 0.0249
208792_s_at CLU Clusterin 0.8122 0.0266
201108_s_at THBS1 Thrombospondin 1 0.9169 0.0276
201058_s_at MYL9 Myosin, light chain 9, regulatory 0.5909 0.0287
206390_x_at PF4 Platelet factor 4 (chemokine [C-X-Cmotif]
ligand 4)
0.9017 0.0296
206655_s_at GP1BB Glycoprotein Ib (platelet), beta polypeptide 0.8934 0.0317
209651_at TGFB1I1 Transforming growth factor beta 1–induced
transcript 1
0.7618 0.0326
207414_s_at PCSK6 Proprotein convertase subtilisin/kexin type 6 0.8566 0.0351
200665_s_at SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 0.8261 0.0410
212077_at CALD1 Caldesmon 1 0.5688 0.0505
203817_at GUCY1B3 Guanylate cyclase 1, soluble, beta 3 0.8511 0.0546
227088_at PDE5A Phosphodiesterase 5A, cGMP-speciﬁc 0.918 0.0571
226152_at TTC7B Tetratricopeptide repeat domain 7B 0.7986 0.0594
206167_s_at ARHGAP6 Rho GTPase-activating protein 6 0.8437 0.0677
37966_at PARVB Parvin, beta 0.7708 0.0717
208601_s_at TUBB1 Tubulin, beta 1 0.5959 0.0736
204115_at GNG11 Guanine nucleotide–binding protein
(G protein), gamma 11
0.5622 0.1229
Continued on the next page
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Table 1 Continued
Affymetrix Probe ID Gene Symbol
Gene
Description
Combined PFS
Beta Coefﬁcient*
Combined
p Value
241133_at PRSS1 Protease, serine, 1 (trypsin 1) 0.4814 0.1243
203680_at PRKAR2B Protein kinase, cAMP dependent,
regulatory, type II, beta
0.5049 0.1365
205442_at MFAP3L Microﬁbrillar-associated protein 3–like 0.4724 0.1385
212151_at PBX1 Pre-B-cell leukemia transcription factor 1 0.6059 0.1729
212573_at ENDOD1 Endonuclease domain–containing 1 0.7276 0.1735
230690_at TUBB1 Tubulin, beta 1 0.578 0.1864
230645_at FRMD3 FERM domain–containing 3 0.6391 0.2102
225974_at TMEM64 Transmembrane protein 64 0.38321 0.2227
1553842_at BEND2 Chromosome X open reading frame 20 0.5657 0.2258
228708_at RAB27B RAB27B, member Ras oncogene family 0.4836 0.2512
227180_at ELOVL7 ELOVL family member 7, elongation
of long-chain fatty acids (yeast)
0.3943 0.2823
212148_at PBX1 Pre-B-cell leukemia transcription factor 1 0.3139 0.2970
203414_at MMD Monocyte to macrophage
differentiation–associated
0.4287 0.3236
1552773_at CLEC4D C-type lectin domain family 4,
member D
0.37545 0.3543
222717_at SDPR Serum deprivation response
(phosphatidylserine binding protein)
0.3009 0.3830
224823_at MYLK Myosin, light chain kinase 0.2911 0.4644
214974_x_at CXCL5 Chemokine (C-X-C motif) ligand 5 0.1621 0.5011
229778_at C12ORF39 Chromosome 12 open reading frame 39 0.2032 0.5020
235331_x_at PCGF5 Polycomb group ring ﬁnger 5 0.22781 0.5470
212651_at RHOBTB1 Rho-related BTB domain–containing 1 0.2395 0.5755
206110_at HIST1H3H Histone cluster 1, H3h 0.2021 0.5827
215779_s_at HIST1H2BG Histone cluster 1, H2bg 0.2623 0.5896
207815_at PF4V1 Platelet factor 4 variant 1 0.0927 0.6139
226188_at LGALSL Lectin, galactoside-binding–like 0.23728 0.6142
221556_at CDC14B CDC14 cell division cycle 14
homolog B (S. cerevisiae)
0.2127 0.6530
207156_at HIST1H2AG Histone cluster 1, H2ag 0.1534 0.6882
210387_at HIST1H2BG Histone cluster 1, H2bg 0.1494 0.6906
225166_at ARHGAP18 Rho GTPase–activating protein 18 0.15541 0.7353
206272_at RAB4A RAB4A, member Ras oncogene family 0.09962 0.7967
210986_s_at TPM1 Tropomyosin 1 (alpha) 0.08749 0.8404
227451_s_at C6ORF79 Chromosome 6 open reading
frame 79
0.0134 0.9791
*The beta coefﬁcient for the expression of either the aggregate expression of the ARS or each probe set represented by the ARS using the combined HV1 and HV2 datasets from a regression model
containing gene expression and cohort (HV1 vs. HV2) with corresponding p values.
ARS ¼ aspirin response signature; cAMP ¼ cyclic adenosine monophosphate; cGMP ¼ cyclic guanosine monophosphate; CTD ¼ carboxyterminal domain; GTPase ¼ guanosine triphosphatase; HV1 ¼
healthy volunteer discovery cohort; HV2¼ healthy volunteer validation cohort; ID ¼ identiﬁer; mRNA ¼messenger ribonucleic acid; NA ¼ not applicable; PFS ¼ platelet function score; RNA ¼ ribonucleic acid.
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1273the inclusion of the ARS improved most measures of risk
discrimination (Table 3, Fig. 5A,Online Table 8). Inclusion of
ITGA2B probe set expression signiﬁcantly improved all
measures of discrimination (Table 3, Fig. 5B, Online Table 8).
Thus, the ARS or the expression of an individual ARS tran-
script such as ITGA2B was an independent prognostic
biomarker for risk for death or MI.
Discussion
We used aspirin as a probe to identify novel genes and bio-
markers associated with platelet function and cardiovascular
events. We hypothesized that administering aspirin while
assaying the blood transcriptome might identify sets of
genes that are related to aspirin’s cardioprotective effect. Weidentiﬁed a set of platelet-enriched, coexpressed genes and
proteins, the ARS, that was reproducibly associated with
platelet function in response to aspirin. When tested as
a prognostic biomarker, the ARS or an individual ARS tran-
script (e.g., ITGA2B) independently and incrementally pre-
dicted the risk for death or MI compared with traditional risk
factors. Our data show that: 1) the genomic response to
a pharmacological “challenge”with aspirin can reveal genes that
underlie platelet function on aspirin and mechanisms respon-
sible for death or MI; and 2) whole-blood RNA proﬁling may
identify novel biomarkers that discriminate individuals at
heightened risk for death or MI.
Transcripts associated with platelet function on aspirin
are associated with cardiovascular events. We found
neither an association between the ARS and the presence of
Table 2
Aspirin Response Signature Proteins Identiﬁed in
Platelet Protein and Their Correlations With PFS
on Aspirin
Protein Name Correlation With PFS p Value
TBB1 0.32 0.02
GP1BB 0.29 0.03
ITA2B 0.29 0.03
ITB3 0.28 0.04
MYL9 0.27 0.05
RB27B 0.26 0.06
LEGL 0.24 0.08
TSP1 0.24 0.08
CALD1 0.22 0.11
SRC8 0.21 0.12
SH3L2 0.20 0.16
CXCL7 0.20 0.15
SDPR 0.18 0.19
PLF4 0.18 0.20
SPRC 0.14 0.31
PDE5A 0.09 0.49
CLUS 0.06 0.67
PFS ¼ platelet function score.
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1274CAD nor overlap between ARS genes previously associated
with CAD (1,6). Instead, we found that the ARS was
associated with death or MI after controlling for CAD and
CAD risk markers. These ﬁndings highlight a unique and
novel role that the biological pathway represented by ARS
genes has in the development of cardiovascular events,
independent of CAD. We conclude that the biology of
aspirin is complex and involves additional mechanisms
beyond inhibiting platelet cyclo-oxgenase-1, and some of
these mechanisms underlie risk for cardiovascular events.
A novel and translatable biomarker of platelet function
in response to aspirin and the risk for cardiovascular
events. Clinicians currently need a readily available bio-
marker for the response to aspirin. Despite the availability of
platelet function assays, their widespread use is severelyFigure 4 A Set of Coexpressed Peripheral Blood Genes Does Not Co
The aggregate expression of coexpressed genes is plotted against the platelet function b
(A) (n ¼ 45) and the healthy volunteer validation cohort (B) (n ¼ 50). Pearson’s correlati
platelet function score.constrained by the need for specialized equipment and
trained personnel. Point-of-care tests are available but require
testing to be completed within hours of phlebotomy; thus,
they are out of reach for the vast majority of outpatients on
aspirin. Furthermore, most patients taking aspirin for chronic
prevention are outpatients in whom results at the point of
care are not required. Instead, testing in central laboratories,
as is common for low-density lipoprotein cholesterol for
statins, would be sufﬁcient for determining aspirin response
in the outpatient setting. Because of the coexpressed nature
of the ARS genes, several individual transcripts (Table 1)
correlated best with platelet function. We demonstrated that
PCR for individual transcripts could be used in lieu of
microarrays (Fig. 3, Online Table 2) for many ARS genes,
thus demonstrating the feasibility of a blood-based diag-
nostic test.
Whole-blood RNA testing is a well-established diagnostic
testing platform. For cardiac allograft rejection and CAD
diagnosis, whole-blood microarray analyses were both tran-
sitioned to a PCR-based platform (6,7): AlloMap (XDx, Inc.,
Brisbane, California) and Corus CAD (CardioDx, Inc., Palo
Alto, California), respectively. AlloMap has been approved by
the U.S. Food and Drug Administration, and both are
covered by major insurers. Therefore, there is a feasible path
for blood-based RNA biomarkers to clinical adoption, Food
and Drug Administration approval, and insurance coverage.
Peripheral blood gene expression proﬁling reveals coex-
pressed transcripts of platelet origin associated with
platelet function in response to aspirin. The genes
underlying variable platelet function on aspirin have been
difﬁcult to identify (21) or explain a small portion of the
observed variability (22). We hypothesized that whole-blood
RNA proﬁling, which de facto contains platelet transcripts,
would yield biological pathways important for the response
to aspirin. We demonstrated that the transcripts represented
by theARS are likely of platelet origin (Online Tables 4 and 5).
When we analyzed platelet-enriched protein, we not onlyrrelate With Native Pre-Aspirin Platelet Function
efore the administration of aspirin (ASA) in the healthy volunteer discovery cohort
on coefﬁcients and p values are reported. ARS ¼ aspirin response signature; PFS ¼
Figure 5 Peripheral Blood Gene Expression Adds Additional Prognostic Information for Death or MI
Patients in the case-control and observational cohorts were combined and analyzed with respect to death or myocardial infarction (MI) outcomes. The receiver-operating
characteristic curves were plotted for predictive models containing cardiovascular risk factors, platelet count, the presence of coronary artery disease, cohort (collectively, CV)
and gene expression for the aspirin response signature (A) or one of its genes ITGA2B (B), or both were compared. The probe set 216956_s_at represents ITGA2B gene
expression. ARS ¼ aspirin response signature.
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1275conﬁrmed the well-known roles of ITGA2B and ITGB3,
but also ascribe new roles to many other platelet genes,
including MYL9, CLU, PPKAR2B, TREML1, and CTTN,
with respect to platelet function on aspirin and cardiovascular
events. Additionally, recent genomewide association studies
identiﬁed a PEAR1 polymorphism associated with platelet
PEAR1 levels and platelet function on aspirin (22). We
excluded the probe set (228618_at) mapping to PEAR1
because its variance (0.21) was below our variance criterion
(0.25; see the Methods section). However, in a post-hoc
analysis, PEAR1 expression was strongly correlated (r ¼ 0.9)
with ARS levels. Therefore, our approach identiﬁed previously
known and novel platelet genes associated with platelet
function in response to aspirin.Table 3 Measures of Discrimination With and Wit
Measure
Traditional
Risk Factors
T
F
Area under ROC curve 0.72
95% CI 0.68–0.76
p Value* NA
Net reclassiﬁcation index
(<10%, 10%–20%, >20%)
d
95% CI
p Value
Net reclassiﬁcation
index (category free)
d
95% CI
p Value
Integrated discrimination
improvement
d
95% CI
p Value
*All p values are for comparisons with “traditional risk factors” model, which in
hyperlipidemia, cohort, and the presence of coronary artery disease. yThe 2169
microarray.
CI ¼ conﬁdence interval; ROC ¼ receiver-operating characteristic; other abbWe observed an association between ARS and platelet
function only after the administration of aspirin, suggesting
that the latent effect of ARS genes on platelet function is
unmasked in response to aspirin. Consistent with these ﬁnd-
ings,whenwe stratiﬁed theCATHGENcohort by aspirin use,
we observed that the association between theARSanddeath or
MI was higher in those using aspirin at the time of catheteri-
zation (OR: 1.4 vs. 1.1 in aspirin users vs. nonusers). We
hypothesize that the molecular mechanisms represented by
the ARS contributes minimally to native platelet function in
the absence of aspirin. By contrast, when platelet cyclo-
oxygenase-1, a protein not represented by the ARS, is sup-
pressed by 325 mg/day aspirin dosing (23), the effects of
these platelet-enriched genes is revealed such that the resultinghout Inclusion of Gene Expression Proﬁles
raditional Risk
actors þ ARS
Traditional Risk
Factors þ 216956_s_aty (ITGA2B)
0.73 0.74
0.69–0.77 0.70–0.78
0.3 0.04
0.06 0.12
0.02–0.10 0.07–0.17
0.005 <1  105
0.31 0.37
0.15–0.47 0.21–0.54
2  104 8.7  106
0.01 0.03
0.002–0.02 0.02–0.05
0.006 2  105
cludes age, sex, African-American race, smoking, diabetes, hypertension,
56_s_at probe set represents ITGA2B gene expression on the Affymetrix
reviations as in Table 1.
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1276level of platelet function is then determined by the ARS.
Alternatively, aspirin exposure may alter the genomic and
protein content of circulating platelets.Theprecisemechanism
bywhichplatelet functionon aspirin is related to the expression
of the ARS genes and proteins on aspirin is the subject of
ongoing work.
Study limitations. Several limitations deserve consider-
ation. Neither platelet function nor MPV was measured in
CATHGEN. Therefore, we cannot know whether height-
ened ARS levels altered platelet function or volumes in
addition to an increased risk for death or MI. To our
knowledge, large cohorts with platelet function, banked
RNA, longitudinal follow-up, and a sufﬁcient number of
events are not available. Furthermore, in our discovery and
validation cohorts, the association of the ARS with PFS was
independent of platelet count and MPV, suggesting that the
ARS provides an independent parameter of platelet function
that underlies cardiovascular events. Second, although there
was no association between the ARS and modiﬁable risk
factors (e.g., diabetes, hyperlipidemia, or hypertension),
because we did not assess the degree to which these risk fac-
tors were controlled, we do not know whether addressing
these risk factors could modulate ARS levels. Finally, the
comparison of the ARS gene set with that of platelets,
megakaryocytes, and platelet proteomics analyses demon-
strate that the top ARS genes correlative of platelet function
on aspirin were of platelet origin. However, some ARS genes
(e.g., TTC7B, FSTL1) are also expressed in nonplatelet cell
types, suggesting that mechanism(s) represented by ARS
genes may involve more than just platelets.
Conclusions
We used aspirin as a probe in conjunction with RNA
proﬁling and identiﬁed novel biomarkers that identify
patients at highest risk for death or MI independent of
clinical risk factors.
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APPENDIX
For an expanded Methods section, and supplementary ﬁgures and tables
and their legends, please see the online version of this article.
